All In Biotech

Drug Trial Radar · NCT07923851

A Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulosis

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulosis

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2027

Study completion Mar 2029

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of SHR-1139 injection.

Conditions

  • Palmoplantar Pustulosis of Adults

Interventions

  • SHR-1139 InjectionDrug

    SHR-1139 Injection.

  • SHR-1139 Injection PlaceboDrug

    SHR-1139 Injection Placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI)Time frame: Baseline to Day 113.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.